January 31, 2018 / 10:17 PM / 9 months ago

BRIEF-Novartis Announces NEJM Publication Of Updated Analysis From Eliana Trial Showing Longer-Term Durable Remissions With Kymriah In Children, Young Adults With R/R ALL

Jan 31 (Reuters) - Novartis AG:

* NOVARTIS ANNOUNCES NEJM PUBLICATION OF UPDATED ANALYSIS FROM ELIANA TRIAL SHOWING LONGER-TERM DURABLE REMISSIONS WITH KYMRIAH™ IN CHILDREN, YOUNG ADULTS WITH R/R ALL

* NOVARTIS AG - ‍IN ANALYSIS OF 75 INFUSED PATIENTS WITH 3 OR MORE MONTHS OF FOLLOW-UP, KYMRIAH DEMONSTRATED AN OVERALL REMISSION RATE OF 81%​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below